{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:44:43Z","timestamp":1780994683807,"version":"3.54.1"},"publisher-location":"Cham","reference-count":43,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031803956","type":"print"},{"value":"9783031803963","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-80396-3_12","type":"book-chapter","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T04:00:08Z","timestamp":1742356808000},"page":"293-307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Systemic Therapies for Advanced Medullary Thyroid Carcinoma"],"prefix":"10.1007","author":[{"given":"Marco Ruiz","family":"Santillan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Dadu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Gagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth G.","family":"Grubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi I.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"issue":"2","key":"12_CR1","doi-asserted-by":"publisher","first-page":"E364","DOI":"10.1210\/jc.2012-2703","volume":"98","author":"N Agrawal","year":"2013","unstructured":"Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, Bhan S, Ho AS, Khan Z, Bishop J, Westra WH, Wood LD, Hruban RH, Tufano RP, Robinson B, Dralle H, Toledo SP, Toledo RA, Morris LG, Ghossein RA, Fagin JA, Chan TA, Velculescu VE, Vogelstein B, Kinzler KW, Papadopoulos N, Nelkin BD, Ball DW (2013) Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 98(2):E364\u2013E369. https:\/\/doi.org\/10.1210\/jc.2012-2703","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"12_CR2","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1089\/thy.2022.0630","volume":"33","author":"O Alsharif","year":"2023","unstructured":"Alsharif O, Panella T, Nodit L, Hu MI (2023) Letter to the Editor: ETV6-NTRK2 fusion identified in a patient with medullary thyroid carcinoma. Thyroid 33(6):774\u2013776. https:\/\/doi.org\/10.1089\/thy.2022.0630","journal-title":"Thyroid"},{"issue":"12","key":"12_CR3","doi-asserted-by":"publisher","first-page":"1569077","DOI":"10.1089\/thy.2013.0137","volume":"23","author":"F Bentzien","year":"2013","unstructured":"Bentzien F, Zuzow M, Heald N et al (2013) In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Thyroid 23(12):1569077","journal-title":"Thyroid"},{"issue":"10","key":"12_CR4","doi-asserted-by":"publisher","first-page":"E2031","DOI":"10.1210\/jc.2012-2092","volume":"97","author":"A Boichard","year":"2012","unstructured":"Boichard A, Croux L, Al Ghuzlan A, Broutin S, Dupuy C, Leboulleux S, Schlumberger M, Bidart JM, Lacroix L (2012) Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab 97(10):E2031\u2013E2035. https:\/\/doi.org\/10.1210\/jc.2012-2092","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"12_CR5","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1210\/jc.2014-2811","volume":"99","author":"ME Cabanillas","year":"2014","unstructured":"Cabanillas ME, Hu MI, Jimenez C (2014) Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat, and with which drug, those are the questions. J Clin Endocrinol Metab 99(12):4390\u20134396","journal-title":"J Clin Endocrinol Metab"},{"issue":"36","key":"12_CR6","doi-asserted-by":"publisher","first-page":"6056","DOI":"10.1038\/sj.onc.1207810","volume":"23","author":"F Carlomagno","year":"2004","unstructured":"Carlomagno F, Guida T, Anaganti S et al (2004) Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23(36):6056\u20136063","journal-title":"Oncogene"},{"key":"12_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3349\/ymj.2017.58.1.9","volume":"58","author":"H Chang","year":"2017","unstructured":"Chang H, Sung JH, Moon SU et al (2017) EGF induced RET inhibitor resistance in CCDC6- RET lung cancer cells. Yonsei Med J 58:9\u201318","journal-title":"Yonsei Med J"},{"issue":"1","key":"12_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1089\/thy.2012.0207","volume":"23","author":"R Ciampi","year":"2013","unstructured":"Ciampi R, Mian C, Fugazzola L et al (2013) Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid 23(1):50\u201357","journal-title":"Thyroid"},{"key":"12_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"12_CR10","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"Elisei R, Schlumberger MJ, M\u00fcller SP et al (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31:3639\u20133646","journal-title":"J Clin Oncol"},{"issue":"8","key":"12_CR11","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1210\/clinem\/dgac325","volume":"107","author":"R Elisei","year":"2022","unstructured":"Elisei R, Ciampi R, Matrone A et al (2022) Somatic RET indels in sporadic medullary thyroid cancer: prevalence and response to selpercatinib. J Clin Endocrinol Metab 107(8):2195\u20132202","journal-title":"J Clin Endocrinol Metab"},{"key":"12_CR12","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3390\/cancers13051091","volume":"13","author":"S Fancelli","year":"2021","unstructured":"Fancelli S, Caliman E, Mazzoni F et al (2021) Chasing the target: new phenomena of resistance to novel selective RET inhibitors in lung cancer. Updated evidence and future perspectives. Cancers (Basel) 13:1091","journal-title":"Cancers (Basel)"},{"issue":"1","key":"12_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.surg.2018.08.029","volume":"165","author":"SB Fisher","year":"2019","unstructured":"Fisher SB, Cote GJ, Bui JH et al (2019) Genetic characterization of medullary thyroid cancer in childhood survivors of the Chernobyl accident. Surgery 165(1):58\u201363","journal-title":"Surgery"},{"key":"12_CR14","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1210\/jc.2005-2401","volume":"91","author":"J Fromigu\u00e9","year":"2006","unstructured":"Fromigu\u00e9 J, De Baere T, Baudin E, Dromain C, Leboulleux S, Schlumberger M (2006) Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab 91:2496\u20132499","journal-title":"J Clin Endocrinol Metab"},{"key":"12_CR15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1530\/ERC-13-0085","volume":"20","author":"ML Gild","year":"2013","unstructured":"Gild ML, Landa I, Ryder M, Ghossein RA, Knauf JA, Fagin JA (2013) Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. Endocr Relat Cancer 20:659\u2013667","journal-title":"Endocr Relat Cancer"},{"issue":"1A","key":"12_CR16","first-page":"305","volume":"28","author":"N Goutas","year":"2008","unstructured":"Goutas N, Vlachodimitropoulos D, Bouka M, Lazaris AC, Nasioulas G, Gazouli M (2008) BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res 28(1A):305\u2013308","journal-title":"Anticancer Res"},{"issue":"3","key":"12_CR17","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1210\/jc.2014-4153","volume":"100","author":"EG Grubbs","year":"2015","unstructured":"Grubbs EG, Ng PK, Bui J et al (2015) RET fusion as a novel driver of medullary thyroid carcinoma. J Clin Endocrinol Metab 100(3):788\u2013793","journal-title":"J Clin Endocrinol Metab"},{"key":"12_CR18","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","volume":"389","author":"J Hadoux","year":"2023","unstructured":"Hadoux J, Elisei R et al (2023a) Phase 3 trail of Selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med 389:1851\u20131861. https:\/\/doi.org\/10.1056\/NEJMoa2309719","journal-title":"N Engl J Med"},{"key":"12_CR19","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00053","volume":"7","author":"J Hadoux","year":"2023","unstructured":"Hadoux J, Al Ghuzlan A, Lamartina L et al (2023b) Patterns of treatment failure after selective rearranged during transfection (RET) inhibitors in patients with metastatic medullary thyroid carcinoma. JCO Precis Oncol 7:e2300053","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"12_CR20","doi-asserted-by":"publisher","first-page":"luae103","DOI":"10.1210\/jcemcr\/luae103","volume":"2","author":"S Hamidi","year":"2024","unstructured":"Hamidi S, Mahvash A, Hu MI (2024) Paraneoplastic diarrhea from medullary thyroid carcinoma resolved with yttrium-90 radioembolization of liver metastases. JCEM Case Rep 2(8):luae103. https:\/\/doi.org\/10.1210\/jcemcr\/luae103","journal-title":"JCEM Case Rep"},{"issue":"7","key":"12_CR21","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1158\/1078-0432.CCR-17-2297","volume":"24","author":"GL Hanna","year":"2018","unstructured":"Hanna GL et al (2018) Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study. Clin Cancer Res 24(7):1546\u20131553. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2297","journal-title":"Clin Cancer Res"},{"issue":"11","key":"12_CR22","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1089\/thy.2019.0041","volume":"29","author":"K Hillier","year":"2019","unstructured":"Hillier K, Hughes A, Shamberger RC et al (2019) A novel ALK fusion in pediatric medullary thyroid carcinoma. Thyroid 29(11):1704\u20131707","journal-title":"Thyroid"},{"issue":"2","key":"12_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1530\/ERC-18-0258","volume":"26","author":"MI Hu","year":"2019","unstructured":"Hu MI, Elisei R, Dedecjus M et al (2019a) Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. Endocr Relat Cancer 26(2):241\u2013250. https:\/\/doi.org\/10.1530\/ERC-18-0258","journal-title":"Endocr Relat Cancer"},{"key":"12_CR24","first-page":"10","volume":"29","author":"MI Hu","year":"2019","unstructured":"Hu MI, Cote GJ, Hai T et al (2019b) Emergence of resistance-associated mutations of RET V804M and KRAS in medullary thyroid carcinoma (MTC) patients treated with tyrosine kinase inhibitors (TKI) cabozantinib and vandetanib. Thyroid 29:10","journal-title":"Thyroid"},{"key":"12_CR25","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1210\/jc.2004-1836","volume":"90","author":"A Machens","year":"2005","unstructured":"Machens A, Schneyer U, Holzhausen HJ, Dralle H (2005) Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 90:2029\u20132034","journal-title":"J Clin Endocrinol Metab"},{"key":"12_CR26","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1365-2265.2009.03666.x","volume":"72","author":"JA Meijer","year":"2010","unstructured":"Meijer JA, le Cessie S, van den Hout WB et al (2010) Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol 72:534\u2013542","journal-title":"Clin Endocrinol"},{"issue":"5","key":"12_CR27","doi-asserted-by":"publisher","first-page":"E863","DOI":"10.1210\/jc.2010-1921","volume":"96","author":"MM Moura","year":"2011","unstructured":"Moura MM, Cavaco BM, Pinto AE, Leite V (2011) High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 96(5):E863\u2013E868. https:\/\/doi.org\/10.1210\/jc.2010-1921","journal-title":"J Clin Endocrinol Metab"},{"key":"12_CR28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41467-018-02994-7","volume":"9","author":"T Nakaoku","year":"2018","unstructured":"Nakaoku T, Kohno T, Araki M et al (2018) A secondary RET mutation in the activation loop conferring resistance to vandetanib. Nat Commun 9:625","journal-title":"Nat Commun"},{"key":"12_CR29","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1158\/1535-7163.MCT-17-0008","volume":"16","author":"SK Nelson-Taylor","year":"2017","unstructured":"Nelson-Taylor SK, Le AT, Yoo M, Schubert L, Mishall KM, Doak A, Varella-Garcia M, Tan A-C, Doebele RC (2017) Resistance to RET-inhibition in RET-rearranged NSCLC is mediated by reactivation of RAS\/MAPK signaling. Mol Cancer Ther 16:1623\u20131633","journal-title":"Mol Cancer Ther"},{"key":"12_CR30","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/cncr.22244","volume":"107","author":"S Roman","year":"2006","unstructured":"Roman S, Lin R, Sosa JA (2006) Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107:2134\u20132142","journal-title":"Cancer"},{"issue":"4","key":"12_CR31","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nrendo.2016.11","volume":"12","author":"C Romei","year":"2016","unstructured":"Romei C, Ciampi R, Elisei R (2016) A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol 12(4):192\u2013202. https:\/\/doi.org\/10.1038\/nrendo.2016.11","journal-title":"Nat Rev Endocrinol"},{"key":"12_CR32","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/s41467-022-28848-x","volume":"13","author":"EY Rosen","year":"2022","unstructured":"Rosen EY et al (2022) The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. Nat Commun 13:1450","journal-title":"Nat Commun"},{"issue":"5","key":"12_CR33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","volume":"17","author":"D Salvatore","year":"2021","unstructured":"Salvatore D, Santoro M, Schlumberger M (2021) The importance of the RET gene in thyroid cancer and therapeutic implications. Nat Rev Endocrinol 17(5):296\u2013306","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"12_CR34","doi-asserted-by":"publisher","first-page":"bvae048","DOI":"10.1210\/jendso\/bvae048","volume":"8","author":"AS Shirali","year":"2024","unstructured":"Shirali AS, Hu MI, Chiang YJ et al (2024) Next-generation sequencing in sporadic medullary thyroid cancer patients: mutation profile and disease aggressiveness. J Endocr Soc 8(6):bvae048. eCollection 2024 Apr 6","journal-title":"J Endocr Soc"},{"key":"12_CR35","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","volume":"29","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Velcheti V, Tuch BB et al (2018a) Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol 29:1869\u20131876","journal-title":"Ann Oncol"},{"key":"12_CR36","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","volume":"8","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Gainor JF, Rahal R et al (2018b) Precision targeted therapy with BLU-667 for RET -driven cancers. Cancer Discov 8:836\u2013849","journal-title":"Cancer Discov"},{"key":"12_CR37","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","volume":"9","author":"V Subbiah","year":"2021","unstructured":"Subbiah V, Hu MI, Wirth LJ et al (2021a) Pralsetinib for patients with advanced or metastatic RET altered thyroid cancer (ARROW): a multi-cohort, open label, registrational, phase 1\/2 study. Lancet Diabetes Endocrinol 9:491\u2013495","journal-title":"Lancet Diabetes Endocrinol"},{"key":"12_CR38","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","volume":"32","author":"V Subbiah","year":"2021","unstructured":"Subbiah V, Shen T, Terzyan SS et al (2021b) Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol 32:261\u2013268","journal-title":"Ann Oncol"},{"issue":"1","key":"12_CR39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1089\/thy.2023.0363","volume":"34","author":"V Subbiah","year":"2024","unstructured":"Subbiah V, Hu MI et al (2024) Pralsetinib in patients with advanced\/metastatic rearranged during transfection (RET)-altered thyroid cancer: updated efficacy and safety data from the ARROW study. Thyroid 34(1):26\u201340","journal-title":"Thyroid"},{"key":"12_CR40","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","volume":"30","author":"SA Wells Jr","year":"2012","unstructured":"Wells SA Jr, Robinson BG, Gagel RF et al (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30:134\u2013141","journal-title":"J Clin Oncol"},{"issue":"6","key":"12_CR41","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells Jr","year":"2015","unstructured":"Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG, American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6):567\u2013610. https:\/\/doi.org\/10.1089\/thy.2014.0335","journal-title":"Thyroid"},{"issue":"9","key":"12_CR42","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"Wirth LJ, Sherman E, Robinson B et al (2020) Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 383(9):825\u2013835","journal-title":"N Engl J Med"},{"issue":"2","key":"12_CR43","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1089\/thy.2023.0279","volume":"34","author":"B Xu","year":"2024","unstructured":"Xu B, Viswanatha K, Ahadi M et al (2024) Association of the genomic profile of medullary thyroid carcinoma with tumor characteristics and clinical outcomes in an international multicenter study. Thyroid 34(2):167\u2013176","journal-title":"Thyroid"}],"container-title":["Recent Results in Cancer Research","Medullary Thyroid Carcinoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-80396-3_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T04:00:12Z","timestamp":1742356812000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-80396-3_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031803956","9783031803963"],"references-count":43,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-80396-3_12","relation":{},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"value":"0080-0015","type":"print"},{"value":"2197-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"20 March 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}